|
|
Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2002-05-1324.

Submitted May 8, 2002
Accepted June 21, 2002
Primitive IL-3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo
Xiaoyan Jiang, Eddy Ng, Calvin Yip, Wolfgang Eisterer, Yves Chalandon, Matthew Stuible, Allen Eaves, and Connie J Eaves*
The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada; Departments of Medicine, Pathology and Laboratory Medicine and Medical Genetics, University of British Columbia, Vancouver, BC, Canada
* Corresponding author; email: ceaves{at}bccancer.bc.ca.
Primitive chronic myeloid leukemia cells display a unique autocrine interleukin-3 (IL-3)/granulocyte colony-stimluating factor (G-CSF) mechanism that may explain their abnormal proliferation and differentiation control. Here we show that BCR-ABL-transduction of primitive Sca-1+ lin- mouse bone marrow (BM) cells causes immediate activation of IL-3, G-CSF and GM-CSF expression in these cells. Their autocrine IL-3-mediated growth dependence is thus demonstrable only in clonal cultures where paracrine effects are reduced. Interestingly, upon continued culture, these cells produce large populations of rapidly proliferating mast cells in which only the IL-3 autocrine mechanism is consistently maintained, together with evidence of hyperphosphorylation of p210BCR-ABL and STAT5 and retention of a multi-lineage but attenuated in vivo leukemogenic potential characterized by a prolonged latency. BCR-ABL-transduction of IL-3-/- Sca-1+ lin- BM cells initially activates GM-CSF and G-CSF production, factor-independence and the ability to generate phenotypically indistinguishable populations of mast cells. However maintenance of factor-independence, and p210BCR-ABL and STAT 5 activation beyond 4-6 weeks requires rescue with an IL-3 transgene. The cultured BCR-ABL-transduced IL-3-/- cells also lack leukemogenic activity in vivo. These findings provide new evidence that IL-3 production is a rapid, sustained and biologically relevant consequence of BCR-ABL expression in primitive hematopoietic cells with multi-lineage leukemogenic activity.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. L. Zhou, Y. Zhao, A. Ringrose, D. DeGeer, E. Kennah, A. E.-J. Lin, G. Sheng, X.-J. Li, A. Turhan, and X. Jiang
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
J. Exp. Med.,
October 27, 2008;
205(11):
2657 - 2671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
J Natl Cancer Inst,
May 2, 2007;
99(9):
680 - 693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang, Y. Zhao, W.-Y. Chan, S. Vercauteren, E. Pang, S. Kennedy, F. Nicolini, A. Eaves, and C. Eaves
Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia
Blood,
May 15, 2004;
103(10):
3897 - 3904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Donato, J. Y. Wu, J. Stapley, H. Lin, R. Arlinghaus, B. Aggarwal, S. Shishodin, M. Albitar, K. Hayes, H. Kantarjian, et al.
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Res.,
January 15, 2004;
64(2):
672 - 677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang, M. Stuible, Y. Chalandon, A. Li, W. Y. Chan, W. Eisterer, G. Krystal, A. Eaves, and C. Eaves
Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia
Blood,
October 15, 2003;
102(8):
2976 - 2984.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wong, J. McLaughlin, D. Cheng, K. Shannon, L. Robb, and O. N. Witte
IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease
PNAS,
September 30, 2003;
100(20):
11630 - 11635.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|